ClinicalTrials.gg
CompletedNCT02182024Updated Jul 18, 2014

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

A Phase 1 interventional study of Dabigatran etexilate high dose and Dabigatran etexilate low dose in Renal Insufficiency, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Renal Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Boehringer Ingelheim.

Enrollment
6th of 11
35 · median 35
Started
2005
the only one that year
Phase 1
10 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Renal Insufficiency by Boehringer Ingelheim, this one is the 6th largest by enrollment, is the only one that started in 2005, is one of 10 in phase 1, and was the 5th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

To assess the effect of different degrees of renal impairment on the pharmacokinetics and pharmacodynamics of dabigatran etexilate administered orally.

03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects determined by results of screening with a >80 mL/min (group 1, control group)
  • Renally impaired male or female subjects determined by results of screening with the following creatinine clearance results:

    • creatinine clearance >50 - ≤80 mL/min (group 2)
    • creatinine clearance >30 - ≤50 mL/min (group 3)
    • creatinine clearance ≤30 mL/min (group 4)
    • uraemia requiring maintenance dialysis (group 5)
    • Signed written in accordance with Good Clinical Practice (GCP) and local legislation
  • Age >=18 and \<=75 years
  • >=18.0 and \<=32 kg/m2, at least 45 kg for females

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate, and ) deviating from normal and of clinical relevance
  • gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy, cholecystectomy or herniotomy)
  • Clinically relevant diseases of the central nervous system
  • Relevant history of orthostatic hypotension, fainting spells or blackouts
  • Abnormal (PT), TT, aPTT (must be within the normal range after no more than one repeated test), \<150000/μl (two repeats of the first test)
  • Evidence of haematuria either macroscopically detectable or microscopic on urinalysis (normal microscopic results after no more than one repeated test)
  • Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, central nervous system (CNS) trauma, retinopathy or nephrolithiasis)
  • Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of CNS or eye or surgery resulting in large open surfaces) within 14 days before or after drug administration of this clinical trial
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • For women with : no reliable (accepted methods are intra uterine device, hormonal contraceptives, bilateral tubal ligation, hysterectomy, condoms) or pregnancy (known or detected by a positive pregnancy test) or breast feeding period
  • Intake of drugs with a long half-life (>24 hours) (\<1 month prior to administration or during the trial)
  • Use of any drugs, within 14 days prior to administration or during the trial
  • Participation in another trial with an drug (\<2 months prior to drug administration or during trial)
  • Drug abuse
  • Blood donation or loss >400 mL, \<1 month prior to administration or during the trial
  • Excessive physical activities \<5 days prior to administration of study drug or during trial
  • Clinically relevant laboratory abnormalities

Renally impaired subjects (groups 2, 3, 4 and 5) who met any of the following criteria were not be entered into this trial:

  • Moderate and severe concurrent liver function impairment (e.g. due to hepatorenal syndrome)
  • Clinically relevant gastrointestinal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy, cholecystectomy or herniotomy)
  • Clinically relevant diseases of the central nervous system
  • Relevant history of orthostatic hypotension, fainting spells or blackouts
  • Abnormal values for PT, TT, aPTT and thrombocytes considered by the investigator or one of the co-investigators to be clinically relevant
  • Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, CNS trauma, retinopathy, nephrolithiasis) considered by the investigator or one of the co-investigators to be clinically relevant
  • Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of CNS or eye or surgery resulting in large open surfaces) within 14 days before or after drug administration of this clinical trial
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • For women with childbearing potential: no reliable contraception (accepted methods are intra-uterine device, hormonal contraceptives, bilateral tubal ligation, hysterectomy or condoms) or pregnancy (known or detected by a positive pregnancy test) or breast-feeding period
  • Participation in another trial with an investigational drug (\<2 months prior to administration or during trial)
  • Drug abuse
  • Blood donation or loss >400 mL, \<1 month prior to administration or during the trial
  • Excessive physical activities \< 5 days prior to administration of study drug or during trial
  • Clinically relevant laboratory abnormalities except those values typical for renally impaired patients
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Dabigatran high dose in healthy subjects

    healthy subjects with a creatinine clearance of \>80 mL/m

    Drug: Dabigatran etexilate high dose

  • Experimental
    Dabigatran high dose in mild renal impairment

    patients with a creatinine clearance of \>50 up to 80 mL/min

    Drug: Dabigatran etexilate high dose

  • Experimental
    Dabigatran high dose in moderate renal impairment

    patients with a creatinine clearance of \>30 up to 50 mL/min

    Drug: Dabigatran etexilate high dose

  • Experimental
    Dabigatran high dose in severe renal impairment

    patients with a creatinine clearance of up to 30 mL/min

    Drug: Dabigatran etexilate high dose

  • Experimental
    Dabigatran low dose in haemodialysis patients

    patients requiring haemodialysis

    Drug: Dabigatran etexilate low dose

Interventions

  • DrugDabigatran etexilate high dose
  • DrugDabigatran etexilate low dose
06

What researchers measure

Primary outcomes

  1. AUC0-infinity (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  2. Cmax (maximum concentration of the analyte in plasma)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  3. CL/F (apparent clearance of the analyte in the plasma after extravascular administration)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  4. international normalized ratio (INR)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  5. activated partial thromboplastin time (aPTT)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  6. Ecarin clotting time (ECT)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  7. thrombin time (TT)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

Secondary outcomes

  1. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  2. AUCt1-t2 (area under the concentration-time curve of the analyte in plasma over the time interval t1 to t2, time interval to be determined)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  3. tmax (time from dosing to the maximum concentration of the analyte in plasma, oral administration only)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  4. λz (terminal rate constant in plasma)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  5. t1/2 (terminal half-life of the analyte in plasma)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  6. MRTpo (mean residence time of the analyte in the body after p.o. administration)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  7. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Time frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after administration, additional 96 h in subjects with severe renal impairment and dialysis patients

  8. Ae0-72 (amount of analyte that is eliminated in urine from the time interval 0 to 72 h)

    Time frame: pre-dose over 12 hours and post dose in fractions of 0 - 12, 12 - 24, 24 - 48, and 48-72 h, additional until 96 h in subjects with severe renal impairment

  9. fe0-72 (fraction of administered drug excreted unchanged in urine from time point 0 to 72 h)

    Time frame: pre-dose over 12 hours and post dose in fractions of 0 - 12, 12 - 24, 24 - 48, and 48-72 h, additional until 96 h in subjects with severe renal impairment

  10. CLR,0-72 (renal clearance of the analyte in plasma from the time point 0 h until the timepoint 72 h)

    Time frame: pre-dose over 12 hours and post dose in fractions of 0 - 12, 12 - 24, 24 - 48, and 48-72 h, additional until 96 h in subjects with severe renal impairment

  11. Plasma protein binding of dabigatran

    Time frame: within 1 h before study drug administration

  12. Changes from baseline in pulse rate

    Time frame: Day 4, Day 5 in patients with renal impairment

  13. Changes from baseline in systolic and diastolic blood pressure

    Time frame: Day 4, Day 5 in patients with renal impairment

  14. Changes from baseline in ECG

    Time frame: Day 4, Day 5 in patients with renal impairment

  15. Changes from baseline in routine laboratory

    Time frame: Day 4, Day 5 in patients with renal impairment

  16. Occurrence of adverse events

    Time frame: up to day 4, up to day 5 in patients with renal impairment

  17. Assessment of tolerability on a 4-point scale

    Time frame: Day 4, Day 5 in patients with renal impairment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a primary completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Apr 2005
Primary completionActual
Mar 2006
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182024
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Apr 2005
Primary completion
Mar 2006
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion